1. Chronic SSRI treatment reverses HIV-1 protein-mediated synaptodendritic damage.
- Author
-
Denton, Adam R., Mactutus, Charles F., Lateef, Almeera U., Harrod, Steven B., and Booze, Rosemarie M.
- Subjects
- *
HIV , *NUCLEUS accumbens , *RATS , *ESCITALOPRAM , *PATHOGENESIS - Abstract
HIV-1 infection affects approximately 37 million individuals, and approximately 50% of seropositive individuals will develop symptoms of clinical depression and/or apathy. Dysfunctions of both serotonergic and dopaminergic neurotransmission have been implicated in the pathogenesis of motivational alterations. The present study evaluated the efficacy of a SSRI (escitalopram) in the HIV-1 transgenic (Tg) rat. Behavioral, neurochemical, and neuroanatomical outcomes with respect to HIV-1 and sex were evaluated to determine the efficacy of chronic escitalopram treatment. Escitalopram treatment restored function in each of the behavioral tasks that were sensitive to HIV-1-induced impairments. Further, escitalopram treatment restored HIV-1-mediated synaptodendritic damage in the nucleus accumbens; treatment with escitalopram significantly increased dendritic proliferation in HIV-1 Tg rats. However, restoration did not consistently occur with the neurochemical analysis in the HIV-1 rat. Taken together, these results suggest a role for SSRI therapies in repairing long-term HIV-1 protein-mediated neuronal damage and restoring function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF